Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

JAMA Oncology, Год журнала: 2022, Номер 9(1), С. 128 - 128

Опубликована: Ноя. 3, 2022

Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality may be more common in patients with cancer treated immunotherapy (IO) immune system activation. Objective To determine the association of baseline immunosuppression and/or IO-based therapies severity cytokine cancer. Design, Setting, Participants This registry-based retrospective cohort study included 12 046 reported Cancer Consortium (CCC19) registry from March 2020 May 2022. The CCC19 is a centralized international multi-institutional current or past diagnosis Records analyzed active previous who had laboratory-confirmed infection SARS-CoV-2 by polymerase chain reaction serologic findings. Exposures Immunosuppression therapy; systemic anticancer therapy (IO non-IO). Main Outcomes Measures primary outcome was 5-level ordinal scale severity: no complications; hospitalized without requiring oxygen; required intensive care unit admission mechanical ventilation; death. secondary occurrence storm. Results median age entire 65 years (interquartile range [IQR], 54-74) 6359 were female (52.8%) 6598 (54.8%) non-Hispanic White. A total 599 (5.0%) received IO, whereas 4327 (35.9%) non-IO therapies, 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior diagnosis. Although difference found IO group compared untreated (adjusted odds ratio [aOR], 0.80; 95% CI, 0.56-1.13, aOR, 0.89; 0.41-1.93, respectively), (vs untreated) worse (aOR, 3.33; 1.38-8.01, 4.41; 1.71-11.38, respectively). Patients receiving also 1.79; 1.36-2.35) 2.32; 1.42-3.79). Conclusions Relevance that COVID-19, administration especially context associated severe clinical outcomes development Trial Registration ClinicalTrials.gov Identifier: NCT04354701

Язык: Английский

---

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

Cancer Cell, Год журнала: 2022, Номер 40(1), С. 103 - 108.e2

Опубликована: Янв. 1, 2022

Язык: Английский

---

Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study

Future Oncology, Год журнала: 2022, Номер 18(10), С. 1235 - 1244

Опубликована: Янв. 27, 2022

To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate factors affecting seropositivity.

Язык: Английский

---

Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany

Journal of Cancer Research and Clinical Oncology, Год журнала: 2023, Номер 149(10), С. 7493 - 7503

Опубликована: Март 24, 2023

Abstract Purpose The aim of our study was to explore the impact COVID-19 pandemic on reported cancer cases in Bavaria, Germany, by comparing pre-pandemic (March 2019 February 2020) and period 2020 2021). Methods Data incident were retrieved from Bavarian Cancer Registry (until 22nd April 2022). We included patients with malignant situ neoplasms pathology departments consistent reporting. calculated number during 95% confidence intervals (CI) Bonferroni correction (α = 0.0018) based a Poisson approach. stratified for malignancy (malignant, situ), tumor site, month year. Results available 30 out 58 (51.7%) Bavaria. Incident dropped 42,857 39,980 (− 6.7%; CI − 8.7%, 4.7%). Reductions higher colon, rectum, skin/melanoma as well liver (> 10.0% reduction) less breast (4.9% reduction). No case reductions observed pancreas, esophagus, ovary, cervix. Percent changes largest 20.9%; 24.7%, 16.8%) January 2021 25.2%; 28.8%, 21.5%) compared previous Declines tended be larger neoplasms. Conclusion Detection diagnosis substantially reduced pandemic. Potential effects, e.g. stage shift tumors or an increase mortality, need monitored.

Язык: Английский

---

An insight into the use of telemedicine technology for cancer patients during the Covid-19 pandemic: a scoping review

BMC Medical Informatics and Decision Making, Год журнала: 2024, Номер 24(1)

Опубликована: Апрель 19, 2024

Abstract Background The use of telemedicine technology has significantly increased in recent years, particularly during the Covid-19 pandemic. This study aimed to investigate for cancer patients Methods was a scoping review conducted 2023. Various databases including PubMed, Web Science, Scopus, Cochrane Library, Ovid, IEEE Xplore, ProQuest, Embase, and Google Scholar search engine were searched. All quantitative, qualitative, mixed-method studies published English between 2020 2022 included. Finally, needed data extracted, results synthesized reported narratively. Results A total 29 articles included this review. showed that teleconsultation, televisit, telerehabilitation common services, video conferencing telephone technologies used these studies. In most cases, healthcare providers preferred services compared face-to-face consultations due their convenience advantages. Furthermore, findings revealed terms clinical outcomes, could effectively reduce anxiety, pain, sleep disorders, hospital admission rates. Conclusion provided valuable insights into various technologies, users’ perspectives, outcomes Overall, positive satisfaction can be expanded, care. Future research needs both non-clinical effectiveness using improving care delivery, which help develop more successful strategies implementing technology.

Язык: Английский

---